







an Open Access Journal by MDPI

Peptide-Based and Hybrid Carriers for Nucleic Acids Delivery

Guest Editors:

Dr. Anton Kiselev

Department of Genomic Medicine, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya Line 3, 199034 Saint-Petersburg, Russia

Dr. Korzhikova-Vlakh Evgenia

1. Institute of Macromolecular Compounds, Russian Academy of Sciences, 199004 St. Petersburg, Russia

2. Institute of Chemistry, Saint-Petersburg State University, 199034 St. Petersburg, Russia

Deadline for manuscript submissions:

closed (20 November 2023)

Message from the Guest Editors

As Guest Editors, we are pleased to announce the launch of a Special Issue of *Pharmaceutics* titled "Peptide-Based and Hybrid Carriers for Nucleic Acid Delivery". Nanoparticles formed by nucleic acids and peptide-based carriers can be a versatile tool for delivery of various genetic constructs (pDNA, siRNA, miRNA, mRNA, etc.) to cells in favor of gene therapy of inherited and acquired diseases. Their advantages include biodegradability and easiness of modification of the structure and amino acid composition. Natural (ligands, various intra- and extracellular signals, etc.) and synthetic (poly)peptide sequences can be used as part of peptide-based and hybrid carriers to overcome the barriers to the transport of therapeutic genetic material into the cells.

We invite you to contribute to the new Special Issue with the aim to gather and feature the latest advances, perspectives, and trends in the development of poly- and oligopeptide and peptide-containing hybrid carriers for the delivery of therapeutic nucleic acids. Both feature articles and literature reviews are acceptable for publication.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us